The possible advantage of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a graft-versus-lymphoma effect. We explored the feasibility and efficacy of allo-HSCT with reduced-intensity (RI) regimens in advanced malignant lymphoma (ML). A total of 20 patients with indolent (n ¼ 9) or aggressive lymphoma (n ¼ 11) received allo-HSCT with an RI regimen (RIST). The preparative regimen consisted of a combination of purine analog and alkylating agent with or without antithymocyte globulin. A total of 11 patients had chemorefractory disease, seven had chemosensitive relapsed disease and two had residual disease. All of the patients received G-CSF-mobilized blood stem cells from HLA-matched siblings. Of the 20 patients, 19 achieved engraftment with acceptable regimen-related toxicities. Seven patients developed grade II-IV acute GVHD and 15 developed chronic GVHD. Of the 15 patients with evaluable disease, 12 achieved a complete response. One died of invasive fusariosis, four subsequently died of GVHD complicated with fungal infection and one died of progressive disease. With a median follow-up of 358 days, the Kaplan-Meier estimates for 1-year overall and progression-free survival were both 70%. The high response rate with low relapse observed in this study suggests that RIST may be an effective alternative curative treatment for patients with advanced ML.
Summary:
The possible advantage of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a graft-versus-lymphoma effect. We explored the feasibility and efficacy of allo-HSCT with reduced-intensity (RI) regimens in advanced malignant lymphoma (ML). A total of 20 patients with indolent (n ¼ 9) or aggressive lymphoma (n ¼ 11) received allo-HSCT with an RI regimen (RIST). The preparative regimen consisted of a combination of purine analog and alkylating agent with or without antithymocyte globulin. A total of 11 patients had chemorefractory disease, seven had chemosensitive relapsed disease and two had residual disease. All of the patients received G-CSF-mobilized blood stem cells from HLA-matched siblings. Of the 20 patients, 19 achieved engraftment with acceptable regimen-related toxicities. Seven patients developed grade II-IV acute GVHD and 15 developed chronic GVHD. Of the 15 patients with evaluable disease, 12 achieved a complete response. One died of invasive fusariosis, four subsequently died of GVHD complicated with fungal infection and one died of progressive disease. With a median follow-up of 358 days, the Kaplan-Meier estimates for 1-year overall and progression-free survival were both 70%. The high response rate with low relapse observed in this study suggests that RIST may be an effective alternative curative treatment for patients with advanced ML. Bone Marrow Transplantation (2003) 32, 131-137. doi:10.1038/sj.bmt.1704118 Keywords: malignant lymphoma; allogeneic transplantation; reduced-intensity regimen Although clinical evidence has been reported regarding a graft-versus-lymphoma (GVL) effect following allogenic hematopoietic stem cell transplantation (allo-HSCT), [1] [2] [3] [4] the feasibility of allo-HSCT has not been fully established in patients with malignant lymphoma (ML). There has been only one prospective study comparing allo-and auto-HSCT for ML, and this found a significantly lower recurrence rate and a trend toward improved disease-free survival after allo-HSCT. 5 Nevertheless, high regimenrelated toxicity (RRT) and treatment-related mortality (TRM) ultimately led to a survival rate equivalent to that with auto-HSCT. This has been suggested also by other studies with a nonrandomized design. [6] [7] [8] Recently, a new strategy for transplantation using a reduced-intensity (RIST) or nonmyeloablative preparative regimen has been developed to reduce RRT while preserving an adequate antitumor effect associated with allo-HSCT. [9] [10] [11] [12] [13] Although the preliminary data appear to be attractive, widely acceptable suitable regimens and indications for this strategy still remain to be established.
RIST is recently in focus as a new promising therapeutic strategy for the treatment of ML. Nagler et al 14 reported the results of 23 patients with refractory lymphoma who were treated with fludarabine-based RIST. Observed RRT was moderate and four patients developed grade II-IV acute graft-versus-host disease (GVHD). Seven patients died of TRM, and overall and disease-free survival rates at 37 months were both 40%, with a relapse rate of 26%. Khouri et al 10 used purine analogs such as fludarabine or cladribine combined with cyclophosphamide as a preparative regimen before RIST. They recently added high-dose rituximab to the preparative regimen for indolent B-cell lymphomas. 15 Their updated report in 20 patients with indolent lymphoma documented that all of the patients achieved complete response (CR) with no relapse within a median follow-up of 21 months. The incidence of grade II-IV acute GVHD was 20%. The actuarial probability of being alive and in remission at 2 years was 84%.
To confirm these encouraging data, we initiated a feasibility study on RIST using purine analogs for the treatment of hematological malignancies. 16 In this report, we focus on patients with relapsed or refractory ML to identify the feasibility and efficacy of this procedure.
Patients and methods

Eligibility criteria
From May 2000 to August 2001, a total of 20 patients with biopsy-confirmed ML, which was judged to be incurable by cytotoxic chemotherapy, were enrolled in this study. They were considered not to be able to tolerate conventional myeloablative HSCT because of age older than 50 years, organ dysfunction or heavy prior treatments such as preceding auto-HSCT. Donor eligibility required an HLA-identical or one-locus mismatched sibling donor determined by serologic typing for HLA A/B and molecular typing for HLA DR. The patient evaluation prior to transplantation included physical examination, bone marrow examination and radiographic studies including CT scan. All patients and donors gave their written informed consent in accordance with the requirements of the Institutional Review Board.
Patient characteristics
The patients' characteristics are shown in Table 1 . Of the 20 patients, Nine had indolent lymphoma (follicular, grade 1, n ¼ 1; follicular, grade 2, n ¼ 6; lymphoplasmacytic, n ¼ 1; splenic marginal zone B, n ¼ 1). The other 11 patients had aggressive lymphoma (mantle cell, n ¼ 2; follicular, grade 3, n ¼ 1; follicular transformed to diffuse large B cell, n ¼ 2; diffuse large B cell, n ¼ 3; anaplastic large cell, n ¼ 1; peripheral T cell, unspecified, n ¼ 2) according to the WHO classification. 17 At the time of enrollment, 11 (55%) had refractory disease (10 patients had chemoresistant relapse after preceding chemotherapy including combination chemotherapies and/or radiotherapy, and one (case 3) had untested relapse after auto-HSCT). Seven (33%) had relapsed after auto-HSCT, and the median interval between auto-HSCT and RIST was 322 days (range 105-1847 days). Four (20%) were in partial response (PR) and five (25%) were in CR at the time of enrollment. The number of chemotherapy regimens prior to RIST ranged from 1 to 8 (median 3), and five (25%) had received local radiotherapy. One patient with central nervous system (CNS) involvement (case 20) had received local irradiation with gammaknife stereotactic radiosurgery, which uses photon energy with gamma beams from multiple cobalt 60 radiation sources. Nine (45%, case 1, 3-8, 12, 14) had received rituximab with or without other cytotoxic agents. Three had chronic hepatitis B, one of whom was infected with precore mutant-type hepatitis B virus (HBV). They received oral lamivudine 100 mg/day for prophylaxis of HBV reactivation. All of these patients were positive for HBs antigen and the HBV DNA load had decreased below the detectable level before transplantation. Among these latter three patients, one also had dilated cardiomyopathy due to previous anthracyclin-containing regimens (case 12). Case 4 had fungal infection (cryptococcosis of the lung) prior to RIST. Positive serology for cytomegalovirus (CMV) in either the donor or recipient was detected in 19 cases. There were 11 sex-mismatched donor-recipient combinations.
Preparative regimens
A total of 18 patients received a fludarabine (FU)-based preparative regimen. Seven received FU/cyclophosphamide (CY): FU 25 mg/m 2 on days À5 to À1 and CY 60 mg/kg on FU 30 mg/m 2 on days À8 to -3 and BU 4 mg/kg on days À6 and À5. Two of these nine patients also received rabbit antithymocyte globulin (ATG, Thymoglobulin; IMTIX-SANGSTAT, Lyons, France), 2.5 mg/kg, for four consecutive days. After initial pilot study of ATG-containing regimen, 9, 16 we used regimen without ATG for HLAmatched related transplantation. 18 Two patients received FU/melphalan: FU 25 mg/m 2 on days À8 to À3 and melphalan 70 mg/m 2 on days À2 and À1. Two received cladribine/BU: cladribine (Leustatin; Ortho Biotech, Raritan, NJ, USA) 0.11 mg/kg on days À8 to -3 and BU 4 mg/ kg on days À6 and À5. 16 One of these 2 patients received additional ATG as described above.
Mobilization and collection of peripheral blood stem cells
Sibling donors received granulocyte colony-stimulating factor (G-CSF) at 5 mg/kg subcutaneously twice a day on days À3 to 0. Leukoapheresis was performed on day 0 using conventional techniques for peripheral blood stem cells (PBSC) collection. The targeted total number of CD34+ cells was 2.0 Â 10 6 cells/kg. If a sufficient number of cells could not be obtained, PBSC collection was repeated on subsequent days. Cells were cryopreserved with the traditional controlled-rate method for cryopreservation or infused directly without cryopreservation. Stored cells were thawed in a 371C water bath, and infused through a central venous catheter at a rate of 10-20 ml/min, without washing. The number of CD34+ cells infused on day 0 ranged between 2.3 and 14.6 (median 3.7) Â 10 6 cells/kg.
Management of infectious complications
Patients were managed in reverse isolation in laminar airflow-equipped rooms. All of the patients received prophylaxis with trimethoprim/sulfamethoxazole or pentamidine against Pneumocystis carinii infection. They also received quinolone and fluconazole for the prophylaxis of bacterial and fungal infection, respectively. Prophylaxis of herpes virus infection using acyclovir was reported previously. 19 Broad-spectrum antibiotics were initiated at the first episode of neutropenic fever. All of the patients were monitored by CMV pp65 antigenemia once a week. If the antigenemia turned positive, preemptive therapy with ganciclovir was initiated as previously described. 20 
Management of GVHD
For prophylaxis for GVHD, 11 patients received cyclosporin A (CsA) alone, 3 mg/kg continuous infusion over 24 h starting on day -1. The other nine patients received CsA and short-term methotrexate (MTX) at a dose of 10 mg/m 2 on day 1 and 7 mg/m 2 on days 3 and 6. Intravenous CsA was switched to oral administration as soon as it became tolerable. In the absence of acute GVHD, CsA was withdrawn by day 100. GVHD was diagnosed by clinical judgment as well as skin or digestive tract biopsies to support the clinical diagnosis. Acute and chronic GVHD were graded according to the consensus criteria. 21, 22 When patients developed grade II-IV acute GVHD, our practice was to initiate 2 mg/kg/day methylprednisolone in addition to CsA. Patients who survived 100 days or longer after transplantation were included in the analysis of chronic GVHD. /l without receiving transfusion. Graft rejection was defined as peripheral blood aplasia and marrow hypoplasia 421 days after transplantation, with no evidence of donor markers revealed by cytogenetic and molecular techniques.
Chimerism analysis
Chimerism was assessed by standard cytogenetic analysis in male/female recipient-donor combinations from bone marrow. In sex-matched recipient-donor combinations, variable number of tandem repeats (VNTR) PCR from unseparated blood lymphocyte was used to document engraftment or residual host-type cells, with residual host or donor cells detected at a sensitivity of 10%. The values are given as a percentage of donor signals.
Regimen-related toxicities
All non-hematological organ dysfunction from day 0 to 28 was considered RRT and graded according to the toxicity scales developed by the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI-CTC version 2.0). TRM was defined as death directly caused by the transplantation procedure.
End points and statistical analysis
The primary end points of this study included durable hematopoietic engraftment and TRM. Secondary end points included RRT, incidence and severity of GVHD, progression-free survival (PFS) and overall survival (OS). Responses to transplantation were defined according to the recommendations of the international working group. 23 The probability of OS, PFS, time to grade II or greater acute GVHD, and time to chronic GVHD were calculated as a function of time with the Kaplan-Meier method from the date of stem cell infusion (day 0). Progression was defined as the day of progression/relapse or death. Surviving patients were censored on the last day of follow-up. These data were calculated as of March 20, 2002 .
Results
Engraftment and chimerism
The recovery of neutrophils and platelets is shown in Table 2 . One patient could not be evaluated for engraftAllo-HSCT in advanced malignant lymphoma TE Tanimoto et al ment because of early death on day 18. The other 19 patients were assessable and all showed sustained engraftment. In one patient, ANC did not decrease below 0.5 Â 10 9 /l. In the remaining 18 patients, the median time for ANC to reach 0.5 Â 10 9 /l was 11 days (range 5-20). Platelet counts did not decrease below 20 Â 10 9 /l in three patients. In the remaining 16 patients, the median time for platelet recovery to above 20 Â 10 9 /l was 17 days (range 8-39). One patient (case 9) with extensive chronic GVHD developed late graft failure after administration of ganciclovir for the empiric treatment of CMV antigenemia. This patient did not respond to G-CSF and finally died of GVHD complicated with invasive aspergillosis on day 142. Chimerism data were available for 18 patients, excluding one who died of invasive fusariosis before engraftment (case 6) and another who was transplanted from a sexmatched sibling donor (case 10) and lacked an informative microsatellite locus for STR-PCR assay. Of these 18 patients, 17 (95%) achieved full donor chimerism by day 100, while one remained in mixed chimerism (Figure 1 ). This patient developed GVHD complicated with severe fungal infection and could not be considered donor leukocyte infusion for mixed chimerism.
Regimen-related toxicities
As shown in Table 2 , seven patients developed grade 3 nonhematological toxicity according to NCI-CTC version 2.0. Grade 3 mucositis was documented in two patients (10%), both of whom received MTX. Two patients who received a preparative regimen containing melphalan developed grade 3 nausea. Two (10%) developed grade 3 elevation of serum levels of transaminase, which resolved spontaneously. HBV reactivation was not observed in any of the three HBV-positive patients. One patient with dilated cardiomyopathy developed elevation of serum creatinine levels, corresponding to grade 3 renal toxicity, which normalized after withdrawal of CsA.
Infectious complications
Neutropenic fever that required the empiric administration of antibiotics occurred in 11 patients. Bacterial bloodstream infection was documented in seven patients (35%). Two patients developed bacteremia before engraftment. After engraftment, five patients developed bacteremia. Four patients developed invasive fungal infection including invasive fusariosis before engraftment (n ¼ 1) and invasive aspergillosis developed in four patients receiving corticosteroid for the treatment of extensive chronic GVHD. All of these patients died despite intensive antifungal treatment. CMV antigenemia developed in 11 patients: 10 responded to the empiric administration of ganciclovir, while the remaining resistant patient (case 13) was successfully treated with foscarnet. No patient developed symptomatic CMV disease.
GVHD
The cumulative incidence of acute and chronic GVHD is shown in Figure 2 . Of the 19 patients who survived more than 30 days, seven (37%) developed grade II-IV acute GVHD on a median of day 25 (range 12-75). GVHD was rated as grade II in three and grade IV in four. One of the nine patients who received CsA and MTX for GVHD prophylaxis developed grade II acute GVHD. In contrast, six of the 11 patients who received CsA alone for GVHD prophylaxis developed grade II-IV acute GVHD. Six patients responded to the administration of methylprednisolone. GVHD was refractory to corticosteroid in one patient, who was successfully treated with mycofenolate mofetil and ATG. A total of 15 of the 19 patients (79%) who survived more than 100 days developed chronic GVHD. Limited and extensive forms were found in four and 11 patients, respectively. Extensive forms were preceded by acute GVHD in eight of the 11 patients. Four patients had flare-up of GVHD while immunosuppressive treatment was being tapered, and eventually died of GVHD.
Disease response and relapse
Current disease status and transplantation outcomes are shown in Table 2 . All of the patients with indolent lymphoma and eight of 11 with aggressive lymphoma achieved CR after transplantation. A total of 11 patients had measurable disease at transplantation and the lesions were followed periodically. The maximal response was CR in nine patients and stable disease (SD) in two. Among the CR patients, the time to maximal response ranged from 20 to 267 days (median 100 days). All of the five patients in CR at transplantation remain in sustained remission. Three of the four patients in PR at transplantation achieved CR, and one died of GVHD and fungal infection without progression of lymphoma. One patient with a history of CNS lymphoma (case 20) relapsed in the CNS on day 105 and subsequently died without further treatment. A total of 11 patients had refractory disease at the time of RIST. Excluding one patient who had aggressive lymphoma and died early, five indolent and five aggressive lymphoma patients achieved CR. Two of these 10 patients did not develop any signs of GVHD.
Progression-free and overall survival
As of March 20, 2002, 14 patients were alive 218-664 days after transplantation, with a median follow-up of 348 days. The other five patients died of transplantation-related complications and one died of progressive disease. Among the 19 patients who survived 4100 days, presence of grade II-IV acute GVHD was a significant adverse factor for OS (P ¼ 0.02). As shown in Figure 3 , the Kaplan-Meier estimated probabilities of PFS and OS for all 20 patients at 12 months were both 70% (95% CI 50-90%).
Discussion
These findings demonstrate that the described purine analog-based preparative regimens are sufficient for the induction of stable engraftment, and our RIST procedure can be applied with acceptable toxicity to older patients or those with organ dysfunction for advanced malignant lymphoma. No fatal toxicity directly related to the preparative regimens was observed in this study and TRM within 100 days of transplantation was only 5%, which was much lower than those reported in previous studies incorporating RIST or conventional HSCT. 3, 24 Furthermore, among seven patients who had received RIST as a second transplantation, only two died of transplant-related complications. Considering the high risk of RRT, most physicians believe that conventional transplantation should be avoided in the second HSCT. 25 Thus, RIST seems to be a promising approach even in the second transplantation. This study suggests that ML can be highly sensitive to allogeneic immunity. Strikingly, all of the 10 patients who had refractory lymphoma and survived for more than 30 days after transplantation eventually achieved complete response within several months following transplantation. The response was observed not only in indolent lymphoma patients, but also in aggressive lymphoma patients. The median 100 days between RIST and the appearance of a maximal response is consistent with the time required for the activation and expansion of antitumor cytotoxic T cells. These results support the hypothesis that indolent lymphoma is susceptible to allogeneic immunity, 3, 26 and suggests that some patients with aggressive lymphoma can also be considered for RIST.
GVHD and opportunistic infection still remain as the major obstacles in allogeneic transplantation despite the use of reduced-intensity regimens. They cause significant morbidity and mortality especially after day 100 of transplantation, as shown in our cohort. The observed incidences of 4grade II acute GVHD was 37%, which was comparable to those in previous reports. 9, 12, 13 The incidence of chronic GVHD was relatively high (82%). This may result from the infusion of PBSC or early withdrawal of CsA. Six patients died after transplantation, and four of these deaths were attributable to GVHD. Currently, most physicians believe that induction of GVHD is essential for the manifestation of a GVL effect to eradicate tumors after RIST. 26 In this study, four patients did not develop either acute or chronic GVHD. Three of these four patients had measurable lesions prior to transplantation, and two achieved CR after transplantation. These findings may raise the possibility that GVHD is not essential for the induction of a GVL effect in RIST for ML.
Although controlling GVHD is an important issue in improving the outcome of RIST, proper GVHD prophylaxis has not yet been established in RIST for ML. In this study, 11 and nine patients, respectively, received CsA alone or a combination of CsA and short-term MTX. There was a trend toward better control in those receiving CsA and short-term MTX. Although lower incidence of acute GVHD may contribute to the improvement of the short-term outcome after RIST for ML, potent immunosuppression could hamper immune-mediated graft-versuslymphoma effect and might increase relapse or disease progression. To evaluate this point, we are currently performing a prospective randomized trial comparing CsA alone vs a combination of CsA and short-term MTX as a prophylaxis for acute GVHD after RIST for hematological malignancies.
There have been few reports concerning infectious complications after RIST, and their clinical features remain unknown. 27, 28 In this study, the incidences of bacterial, fungal and viral infection were 35, 20, and 55%, respectively, which were much higher than those reported previously. 27 Although TRM within 100 days of transplantation was only 5%, TRM beyond day 100 was observed in four of 19 patients and the cause was GVHD complicated with fungal infection. This suggests that fungal infection may be a common cause of death in RIST for patients with ML. Since advanced ML patients are usually exposed to heavy prior treatments, they might be more immunocompromised than patients with other hematological malignancies. In addition, prolonged steroid treatment for GVHD made them more susceptible to infection. Another therapeutic approach including new fungal agents and more effective GVHD treatment is mandatory. Reactivation of CMV infection is another common complication in RIST, and this developed in nine of 19 patients (47%) who survived more than 30 days after transplantation. All of the patients with CMV antigenemia responded well to the preemptive administration of ganciclovir or foscarnet. However, late graft failure was observed after the use of ganciclovir in a patient. As formerly reported by us, a decreased dose of ganciclovir and response-oriented dose adjustment might be an appropriate method to decrease the toxicity without deteriorating efficacy of ganciclovir. 20 In conclusion, although the number of patients is small and the follow-up short, our results show that purine analog-based RIST can produce durable engraftment, fewer TRM and a high clinical response rate in patients with relapsed or refractory ML. These observations provide a rationale for continuing our clinical trials, which should be modified to focus on minimizing toxicities, preventing GVHD and controlling infectious complications. 
